The federal offices that decide which prescription drugs, vaccines, gene therapies and nicotine products reach American patients and consumers now have permanent leaders after more than a year of turnover.
The Department of Health and Human Services announced four selections, filling roles that had been held on an acting basis. Michael Davis, a physician and scientist who previously led teams in the agency's Office of New Drugs, becomes director of the Center for Drug Evaluation and Research. Karim Mikhail, who spent decades in the pharmaceutical and biotechnology industry before joining the FDA, becomes director of the Center for Biologics Evaluation and Research. Bret Koplow, a lawyer who has served at the agency since 2011, becomes director of the Center for Tobacco Products. Jared Seehafer becomes the agency's first deputy commissioner for technology and artificial intelligence.
Personnel news at a federal agency is easy to skip. It belongs on a health news site because these four offices sit between a laboratory result and a pharmacy shelf, and instability in them has practical consequences for patients waiting on decisions.
The Reach of Each Office
CDER is the largest of the group and reviews prescription and over-the-counter drugs, generics, and the manufacturing quality of the facilities that supply them, including the overseas plants that produce most active pharmaceutical ingredients used in the United States. HHS said Davis will focus the center on patient access to affordable critical medicines, the science of drug development and evaluation, and strengthening the domestic and global drug supply chain, priorities that sit inside the agency's stated public health pillars.
CBER regulates biological products, a category that covers vaccines, blood and blood products, and cell and gene therapies. Vaccine licensure decisions and gene therapy approvals both run through this center, which is why its leadership has drawn unusual public attention.
The Center for Tobacco Products decides which e-cigarettes, cigars and nicotine pouches may be legally sold, and sets enforcement policy for products marketed without authorization. That office is directly relevant to the flavored vape enforcement dispute now moving through federal court.
The new deputy commissioner post for technology and artificial intelligence is a structural addition rather than a replacement, reflecting the volume of AI-enabled medical products the agency now reviews.
A Year of Turnover Preceding the Appointments
The instability these appointments are meant to end was substantial and documented.
CDER, which had been led by only a handful of long-tenured officials since its creation in 1987, cycled through five leaders in a single year. Davis had served as deputy center director before becoming acting director in the spring, after the previous interim leader, Tracy Beth Hoeg, was removed. The agency's commissioner, Marty Makary, resigned in May after a little more than a year in the job.
CBER's history was more turbulent still. Vinay Prasad joined and left the agency twice over the course of a year, drawing criticism for positions on rare disease drugs, vaccines and gene therapies. A brief acting appointment followed, lasting about three weeks, before Mikhail stepped in.
Industry analysts and investors read the appointments as a return toward routine operations. That framing has limits. Continuity in a director's chair does not by itself resolve review backlogs, staffing losses or the litigation the agency currently faces, including a suit filed by a major tobacco company over the timeliness of product reviews. A permanent commissioner is still pending: the White House put forward policy aide Heidi Overton in August, and her confirmation is not assured.
The Consequences That Land on Households
The connection between an FDA org chart and a household is indirect but real, and it runs through three channels.
The first is timing. Review decisions on new drugs, biosimilars, and generics determine when a treatment becomes available and when lower-cost competition enters a market. Leadership churn slows decisions and creates unpredictability for the companies preparing submissions, which shows up months later as delayed launches.
The second is supply. CDER oversees manufacturing quality inspections, including the foreign facilities that supply most active ingredients used in American medicines. Actions in that area, such as import alerts that halt shipments from a noncompliant plant, protect patients but can also tighten supply of specific generic drugs. The stated focus on supply chain strengthening is the agency's own acknowledgment of that tension.
The third is vaccine and therapy access. CBER's decisions determine which vaccines are licensed and for whom, which flows into insurance coverage and pharmacy availability. For families making fall and winter respiratory vaccination decisions, or for patients waiting on a gene therapy for a rare disease, that office's stability is not abstract.
None of this changes anything a patient should do today. Prescriptions, vaccination schedules and coverage are unaffected by an appointment announcement. What is worth watching over the coming months is whether review timelines for pending applications improve, how the tobacco center handles the unauthorized flavored products currently on shelves, and how the pending litigation over the agency's enforcement guidance resolves. The agency posts its decisions and guidance through the FDA newsroom, which remains the primary public record.
Key Questions Answered
Who was appointed? Michael Davis as CDER director, Karim Mikhail as CBER director, Bret Koplow as director of the Center for Tobacco Products, and Jared Seehafer as the FDA's first deputy commissioner for technology and artificial intelligence.
Were they already in these roles? Three were serving in an acting capacity and now hold the roles permanently. The deputy commissioner position is newly created.
What does CDER control? Review of prescription and over-the-counter drugs and generics, plus oversight of manufacturing quality at domestic and foreign facilities.
What does CBER control? Vaccines, blood and blood products, and cell and gene therapies, including licensure decisions.
Does this change anything for patients now? No. Prescriptions, vaccination schedules, and insurance coverage are unaffected by the announcement itself.
What should readers watch? Whether review timelines improve, how the tobacco center addresses unauthorized flavored vapes on shelves, and the outcome of pending litigation over enforcement guidance.
